Sunovion Answers Is Named a J.D. Power 2021 Certified Customer Service ProgramSM

Sunovion Pharmaceuticals Inc. announced that the Company’s support services program, Sunovion Answers, has been named as a J.D. Power 2021 Certified Customer Service ProgramSM.

Oct. 12, 2021 13:00 UTC

Sunovion’s support services program is recognized three years in a row by J.D. Power for providing an outstanding customer service experience

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the Company’s support services program, Sunovion Answers, has been named as a J.D. Power 2021 Certified Customer Service ProgramSM. Sunovion Answers has been recognized three years in a row under the J.D. Power Certified Customer Service ProgramSM for providing “An Outstanding Customer Service Experience” for Phone support.

“We are proud to earn another J.D. Power Certified Customer Service Program certification for Sunovion Answers, a distinction that reinforces our commitment to serve and create value for patients, a hallmark of our company’s philosophy and approach to everything we do,” said Antony Loebel, M.D., President and Chief Executive Officer, Sunovion Pharmaceuticals Inc. “Our team is dedicated to providing a consistently high level of personalized support and resources to help people living with serious medical conditions.”

“For the fourth time, Sunovion Answers has been recognized for providing, ‘An Outstanding Customer Service Experience’ for Phone support, which is a significant accomplishment,” said Mark Miller, Practice Leader, Customer Service Advisory at J.D. Power. “This certification is difficult to achieve and it is clear that Sunovion is a company committed to helping patients get the support they need through the outstanding service provided.”

Sunovion Answers is designed to provide personalized assistance for patients, their caregivers and health care providers. Sunovion Answers Support Specialists provide live phone support and offer medication information, insurance benefits information and copay savings options to callers. They also help patients find support groups and other resources for further assistance. Sunovion has achieved J.D. Power certification through the J.D. Power Certified Customer Service ProgramSM in 2021, 2020, 2019 and 2017. This recognition is based on successfully completing an evaluation and exceeding a customer satisfaction benchmark through a survey of recent servicing interactions. For more information visit www.jdpower.com/ccc.

About Sunovion Pharmaceuticals Inc. (Sunovion)

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co. and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, is a wholly-owned direct subsidiary of Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s websites: www.sunovion.com and www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

© 2021 Sunovion Pharmaceuticals Inc. All rights reserved.

For a copy of this release, visit Sunovion’s web site at www.sunovion.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005391/en/

Contacts

Jennifer Baird
Executive Director, Corporate Communications
Sunovion Pharmaceuticals Inc.
781-708-2309
jennifer.baird@sunovion.com

Source: Sunovion Pharmaceuticals Inc.

MORE ON THIS TOPIC